Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
Stock Information for Purple Biotech Ltd.
Loading
Please wait while we load your information from QuoteMedia.